AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.00771-07v1
51/12/4505    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Carson, K. C.
Right arrow Articles by Riley, T. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carson, K. C.
Right arrow Articles by Riley, T. V.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2007, p. 4505-4507, Vol. 51, No. 12
0066-4804/07/$08.00+0     doi:10.1128/AAC.00771-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

In Vitro Susceptibility of Methicillin-Resistant Staphylococcus aureus and Methicillin-Susceptible Staphylococcus aureus to a New Antimicrobial, Copper Silicate{triangledown}

Kerry C. Carson,1* Jessica G. Bartlett,1 Trina-Jean Tan,1 and Thomas V. Riley1,2

Microbiology and Infectious Disease, PathWest Laboratory Medicine WA,1 Microbiology and Immunology, The University of Western Australia, Queen Elizabeth II Medical Centre, Nedlands, Western Australia 6009, Australia2

Received 15 June 2007/ Returned for modification 12 July 2007/ Accepted 21 September 2007


   ABSTRACT
Top
 ABSTRACT
TEXT
 REFERENCES
 
The soluble copper silicate (CS) MIC of 100 strains of methicillin-resistant Staphylococcus aureus and 100 strains of methicillin-susceptible S. aureus (MSSA) was 175 mg Cu/liter. Bactericidal and postantibiotic effects (≥1 h) were seen at 2x MIC and 4x MIC. The frequency of mutation was <10–9, and serial passage could not extend growth beyond 1.6x MIC.


   TEXT
Top
 ABSTRACT
 TEXT
REFERENCES
 
Staphylococcus aureus is a commensal bacterium and also a major human pathogen. It may be carried transiently on the skin or for several months in the mucus membranes of the nasal passages. People who persistently carry S. aureus are at an increased risk of subsequent infection (12). Topical antibiotics, such as mupirocin or neomycin, have been used to eliminate S. aureus carriage in high-risk groups of hospitalized patients (6, 13, 14).

In nature copper silicate (CS; chrysolla) is an insoluble, amorphous blue-green mineral found within copper ore bodies. A novel, solubilized form of CS has been developed by Convé PLC as a topical antimicrobial that contains 0.28% (wt/wt) as copper, or 2,800 mg Cu/liter. The CS solution used in this study was manufactured by Patheon Inc. (Toronto, Canada) on 12 December 2005.

The 200 isolates of S. aureus and S. aureus ATCC 29213 used were obtained from the PathWest Laboratory Medicine WA (Nedlands, Western Australia, Australia) culture collection of bacteria isolated from normally sterile anatomical sites. All clinical isolates were identified by microbiology staff at PathWest Laboratory Medicine WA using standard techniques.

The MIC was assayed in Mueller-Hinton broth (MHB) using the Clinical and Laboratory Standards Institute (CLSI) guidelines for susceptibility testing of aerobic bacteria by broth microdilution (3). The copper concentration was taken as the known amount of copper (wt/wt) in the CS solution and did not necessarily reflect the free copper ions available in the MHB. The MIC for CS was remarkably consistent, as all S. aureus strains, including the control strain, S. aureus ATCC 29213, had an MIC of 175 mg Cu/liter. In comparison, the copper sulfate MIC for 20 strains (10 methicillin-resistant S. aureus [MRSA] strains and 10 methicillin-susceptible S. aureus [MSSA] strains) was 1 dilution higher, at 350 mg Cu/liter. The minimal bactericidal concentration (MBC) of CS ranged from 175 to 700 mg Cu/liter, with a 50% MBC (MBC50) and MBC90 of 350 mg Cu/liter for both MRSA and MSSA. There was no evidence of a more resistant subgroup within the total population tested.

Time-kill kinetics showed that CS at the MIC was inhibitory. Bactericidal effects at 2x MIC were strain dependent, as only MRSA 101 was inhibited, while a total kill (99.9%) of S. aureus ATCC 29213 was achieved in 28 min (Fig. 1A and B). At 4x MIC, a total kill for both MRSA 101 and S. aureus ATCC 29213 occurred at 28 min and 10 min, respectively (Fig. 1A and B).


Figure 1
View larger version (6K):
[in this window]
[in a new window]

  		FIG. 1. Time-kill curves of CS in MHB over a 4-h period with MRSA 101 (A) and S. aureus ATCC 29213 (B) and concentrations at MIC, 2x MIC, and 4x MIC. {blacksquare}, growth control; 2MIC, 2x MIC; 4MIC, 4x MIC; dashed lines, total kill. The experiments were conducted a minimum of three times and the results normalized. The standard error of each data point is shown.

 
The capacity of CS to cause a postantibiotic effect (PAE) in MRSA 101, MRSA 102, and S. aureus ATCC 29213 was investigated. MRSA 102 was included, as it had a MBC of 700 mg Cu/liter, 1 dilution higher than that of MRSA 101 and S. aureus ATCC 29213. After a 30-min exposure to CS at the MIC, growth of MRSA 101 and MRSA 102 was unaffected. However, S. aureus ATCC 29213 had an extended lag phase of 2 to 2.5 h, and the time taken for the 10-fold increase was significantly different (P < 0.05) from the that for the control (Table 1). When exposed to 2x MIC, all three strains took a significantly longer time than the control to increase 10-fold (Table 1). The PAE was considered to be significant only when the corresponding time for the 10-fold increase in the viable count was significantly different from that for the control (P < 0.05). Therefore, a significant PAE was seen at the MIC with S. aureus ATCC 29213 and with all three strains at twice the MIC (Table 1).


View this table:
[in this window]
[in a new window]

  		TABLE 1. Time for a 10-fold increase and the calculated PAE for MRSA 101, MRSA 102, and S. aureus ATCC 29213 after 30-min exposure to CSa

 
Spontaneous-resistance studies with mupirocin have shown that S. aureus produces a small population of resistant mutants, with MICs of 1 to 4 mg/liter, at a frequency of 1 to 4 per 109 bacterial cells (2). In similar studies with CS at 2x MIC and 4x MIC, no resistant mutants were detected (Table 2). In serial-passage experiments to induce tolerance or resistance, a twofold increase in the MIC was recorded for two of nine phenotypically distinct isolates capable of growth at 275 mg Cu/liter (1.6x MIC). Nevertheless, this did not represent a significant change in susceptibility as it was less than a fourfold difference. Thus, it appears that tolerance or resistance to CS cannot be readily induced in S. aureus.


View this table:
[in this window]
[in a new window]

  		TABLE 2. Viable count and frequency of mutation of MRSA 101, MRSA 102, MSSA 1, and S. aureus ATCC 29213 with rifampin and CSa

 
The most intensive study of copper homeostasis and resistance in gram-positive bacteria has been with the enterococci (7, 8, 15). Nothing is known of copper homoeostasis or resistance in S. aureus, though genomic sequencing has identified a putative copA gene in both MRSA and MSSA (5, 10, 13). The copper sulfate MIC range for Enterococcus hirae and Enterococcus faecium has been recorded at 127 to 508 mg Cu/liter (1, 9), a very similar result to that recorded for S. aureus in this study with CS. In enterococci, acquired copper resistance has been linked to a transferable plasmid that harbors the copper resistance operon (tcrYAZB), which increased the copper MIC sevenfold to 1,525 mg Cu/liter and also transferred resistance to tetracycline, kanamycin, and streptomycin, either singly or in combination with resistance to macrolides and glycopeptides (7, 9). The plasmid also carried the transposable element Tn1546 (8). S. aureus has acquired vancomycin resistance from an interspecies transfer of the Tn1546 element from Enterococcus faecalis (16), but the possibility of the tcrYAZB operon being transferred in such a manner is unknown.

Mupirocin is the current agent of choice for MRSA eradication in colonized patients and health care workers (11). Widespread clinical use of mupirocin has resulted in mutants with low (8 to 256 mg Cu/liter) and high (≥512 mg Cu/liter) levels of resistance; the increasing prevalence of these mutants gives impetus to the need to find alternative topical antimicrobials for the control of MRSA carriage (4).

CS has in vitro antimicrobial activity against of S. aureus, including MRSA. The data in this study suggest that topical formulations of this antimicrobial may be useful in nasal decolonization therapy and treatment of dermatological infections. Convé PLC has produced a topical cream formulation (0.22% Cu, wt/wt) that has been well tolerated by over 350 people in phase 1 studies. However, clinical trials would need to be conducted to see if these promising in vitro results are a true indication of the potential of CS.

(These results were presented at the joint meeting of the 17th European Congress of Clinical and Infectious Diseases and the 25th International Congress of Chemotherapy, Munich, Germany, 31 March to 3 April 2007.)


   ACKNOWLEDGMENTS
 
This research was fully funded by Convé Ltd., a subsidiary of Convé PLC in which K. C. Carson is a shareholder.


   FOOTNOTES
 
* Corresponding author. Mailing address: Division of Microbiology & Infectious Diseases, PathWest Laboratory Medicine WA, Locked Bag 2009, Nedlands, Western Australia 6909, Australia. Phone: 61 8 9346 4092. Fax: 61 8 9382 8046. E-mail: k-carson{at}cyllene.uwa.edu.au Back

{triangledown} Published ahead of print on 1 October 2007. Back


   REFERENCES
Top
 ABSTRACT
 TEXT
 REFERENCES
 

  1. Aarestrup, F. M., and H. Hasman. 2004. Susceptibility of different bacterial species isolated from food animals to copper sulphate, zinc chloride and antimicrobial substances used for disinfection. Vet. Microbiol. 100:83-89.[CrossRef][Medline]
  2. Casewell, M., and R. Hill. 1985. In vitro activity of mupirocin ('pseudomonic acid') against clinical isolates of Staphylococcus aureus. J. Antimicrob. Chemother. 15:523-531.[Abstract/Free Full Text]
  3. CLSI. 2006. Performance standards for antimicrobial testing; 16th informational supplement (M100-S16). Clinical and Laboratory Standards Institute, Wayne, PA.
  4. Deshpande, L. M., A. M. Fix, M. A. Pfaller, R. N. Jones, and the SENTRY Antimicrobial Surveillance Program Participants Group. 2002. Emerging elevated mupirocin resistance rates among staphylococcal isolates in the SENTRY Antimicrobial Surveillance Program (2000): correlations of results from disk diffusion, Etest and reference dilution methods. Diag. Microbiol. Infect. Dis. 42:283-290.[CrossRef][Medline]
  5. Diep, B. A., S. R. Gill, R. F. Chang, T. H. Phan, J. H. Chen, M. G. Davidson, F. Lin, J. Lin, H. A. Carleton, E. F. Mongodin, G. F. Sensabaugh, and F. Perdreau-Remington. 2006. Complete genome sequence of USA300, an epidemic clone of community-acquired methicillin-resistant Staphylococcus aureus. Lancet 367:731-739.[CrossRef][Medline]
  6. Farr, B. M. 2002. Mupirocin to prevent S. aureus infections. N. Engl. J. Med. 346:1905-1906.[Free Full Text]
  7. Hasman, H. 2005. The tcrB gene is part of the tcrYAZB operon conferring copper resistance in Enterococcus faecium and Enterococcus faecalis. Microbiology 151:3019-3025.[Abstract/Free Full Text]
  8. Hasman, H., and F. M. Aarestrup. 2005. Relationship between copper, glycopeptide, and macrolide resistance among Enterococcus faecium strains isolated from pigs in Denmark between 1997 and 2003. Antimicrob. Agents Chemother. 49:454-456.[Abstract/Free Full Text]
  9. Hasman, H., and F. M. Aarestrup. 2002. tcrB, a gene conferring transferable copper resistance in Enterococcus faecium: occurrence, transferability, and linkage to macrolide and glycopeptide resistance. Antimicrob. Agents Chemother. 46:1410-1416.[Abstract/Free Full Text]
  10. Holden, M. T. G., E. J. Feil, J. A. Lindsay, S. J. Peacock, N. P. J. Day, M. C. Enright, T. J. Foster, C. E. Moore, L. Hurst, R. Atkin, A. Barron, N. Bason, S. D. Bentley, C. Chillingworth, T. Chillingworth, C. Churcher, L. Clark, C. Corton, A. Cronin, J. Doggett, L. Dowd, T. Feltwell, Z. Hance, B. Harris, H. Hauser, S. Holroyd, K. Jagels, K. D. James, N. Lennard, A. Line, R. Mayes, S. Moule, K. Mungall, D. Ormond, M. A. Quail, E. Rabbinowitsch, K. Rutherford, M. Sanders, S. Sharp, M. Simmonds, K. Stevens, S. Whitehead, B. G. Barrell, B. G. Spratt, and J. Parkhill. 2004. Complete genomes of two clinical Staphylococcus aureus strains: evidence for the rapid evolution of virulence and drug resistance. Proc. Natl. Acad. Sci. USA 101:9786-9791.[Abstract/Free Full Text]
  11. Hurdle, J. G., A. J. O'Neill, and I. Chopra. 2005. Prospects for aminoacyl-tRNA synthetase inhibitors as new antimicrobial agents. Antimicrob. Agents Chemther. 49:4821-4833.[Free Full Text]
  12. Kluytmans, J., A. van Belkum, and H. Verbrugh. 1997. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin. Microbiol. Rev. 10:505-520.[Abstract]
  13. Kuroda, M., T. Ohta, I. Uchiyama, T. Baba, H. Yuzawa, I. Kobayashi, L. Cui, A. Oguchi, K.-I. Aoki, Y. Nagai, J. Lian, T. Ito, M. Kanamori, H. Matsumaru, A. Maruyama, H. Murakami, A. Hosoyama, Y. Mizutani-Ui, N. K. Takahashi, T. Sawano, R.-I. Inoue, C. Kaito, K. Sekimizu, H. Hirakawa, S. Kuhara, S. Goto, J. Yabuzaki, M. Kanehisa, A. Yamashita, K. Oshima, K. Furuya, C. Yoshino, T. Shiba, M. Hattori, N. Ogasawara, H. Hayashi, and K. Hiramatsu. 2001. Whole genome sequencing of methicillin-resistant Staphylococcus aureus. Lancet 357:1225-1240.[CrossRef][Medline]
  14. Lowy, F. 1998. Staphylococcus aureus infections. N. Engl. J. Med. 339:520-532.[Free Full Text]
  15. Odermatt, A., H. Suter, R. Krapf, and M. Solioz. 1993. Primary structure of two P-type ATPases involved in copper homeostasis in Enterococcus hirae. J. Biol. Chem. 268:12775-12779.[Abstract/Free Full Text]
  16. Weigel, L. M., D. B. Clewell, S. R. Gill, N. C. Clark, L. K. McDougal, S. E. Flannagan, J. F. Kolonay, J. Shetty, G. E. Killgore, and F. C. Tenover. 2003. Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus. Science 301:1569-1571.

Antimicrobial Agents and Chemotherapy, December 2007, p. 4505-4507, Vol. 51, No. 12
0066-4804/07/$08.00+0     doi:10.1128/AAC.00771-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.00771-07v1
51/12/4505    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Carson, K. C.
Right arrow Articles by Riley, T. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carson, K. C.
Right arrow Articles by Riley, T. V.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS